Boehringer-Ingelheim
Foundation Medicine, Boehringer Ingelheim Collaborate on CDx for Biliary Tract Cancer Drug
The companies will develop the FoundationOne CDx test as a companion diagnostic for Boehringer Ingelheim's BI 907828 in the US, Japan, and EU.
Roche EGFR Mutation Test Approved by FDA as Companion Diagnostic for NSCLC
Roche's real-time PCR test detects defined mutations of the epidermal growth factor receptor gene in DNA from non-small cell lung cancer patients.
Qiagen Gets FDA OK for Expanded Use of EGFR CDx for Lung Cancer Drug
An extended labeling claim has added detection of three additional EGFR mutations to help ID NSCLC patients for whom Boehringer Ingelheim's Gilotrif is indicated.
The lead investigators said that Foundation Medicine's NGS test will enable the beginning of targeted treatment within seven days of diagnosis.